Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

Presentation THT 2026

Serial Echocardiography After Greater Splanchnic Nerve Ablation In Hfpef Demonstrates Reductions In LV Filling Pressures In Clinical Responders But Not In Nonresponders: 12 Month Follow Up In The REBALANCE-HF Trial

Presenter: Sheldon E. Litwin

March 04, 2026

Presentation THT 2026

Advances in Afib Ablation Strategies: What Does the HF Doctor Need To Know?

Presenter: Hirad Yarmohammadi

March 03, 2026

Presentation THT 2026

Managing Persistent Atrial Fibrillation in HF: Medications vs AV Node Ablation/Pacing vs AF Ablation

Presenter: Andrea Russo

March 03, 2026

Presentation THT 2026

Splanchnic Nerve Ablation for Treatment of HF Across the Spectrum of LV EFs

Presenter: Parag Goyal

March 03, 2026

Presentation THT 2025

GSN Ablation Reduces Estimated Stressed Blood Volume in HFpEF: Supports REBALANCE-HF Mechanism of Action

Presenter: Marat Fudim

February 13, 2025

Presentation THT 2025

Case Presentation

Presenter: Catherine Ireland

February 12, 2025

Presentation THT 2025

Position 2: All You Need Is Rate Control

Presenter: Akshay Desai

February 12, 2025

Presentation THT 2025

Position 1: Ablate

Presenter: Roderick Tung

February 12, 2025

Presentation THT 2025

Win Ratio Analysis of Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: REBALANCE-HF Randomized Trial

Presenter: Marat Fudim

February 12, 2025

Presentation THT 2025

Greater Splanchnic Nerve Ablation for HFpEF

Presenter: Sheldon Litwin

February 12, 2025

Presentation THT 2025

Is There a Difference in the Benefits of AF Ablation in HFrEF vs HFpEF?

Presenter: Andrea Russo

February 11, 2025

Presentation THT 2024

The Role of AF Ablation in HF Across the Spectrum of Ejection Fractions

Presenter: Kevin Makati

March 05, 2024

Presentation THT 2024

PVC-Induced Cardiomyopathy: Ablation Is the Treatment of Choice

Presenter: William Hucker

March 05, 2024

Presentation THT 2024

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: REBALANCE-HF Randomized Trial 12-Month Results

Presenter: Sanjiv J. Shah

March 05, 2024

Presentation THT 2024

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: Differences in Medication Changes in in the Sham and Treatment groups of REBALANCE-HF

Presenter: Sheldon E. Litwin

March 04, 2024

Presentation THT 2024

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: REBALANCE-HF Stress Blood Volume Analysis

Presenter: Marat Fudim

March 04, 2024

Presentation THT 2023

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: Updated Results of the REBALANCE-HF Trial Roll-in Cohort

Presenter: Marat Fudim

March 21, 2023

Presentation THT 2022

Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

Long-term follow-up on FIH experience using the Satera Ablation System in HFpEF and HFrEF

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

Overview of the physiology of the splanchnic bed in HFpEF and HFrEF

Presenter: Marat Fudim

February 01, 2022

Advertisement

Serial Echocardiography After Greater Splanchnic Nerve Ablation In Hfpef Demonstrates Reductions In LV Filling Pressures In Clinical Responders But Not In Nonresponders: 12 Month Follow Up In The REBALANCE-HF Trial

Advances in Afib Ablation Strategies: What Does the HF Doctor Need To Know?

Managing Persistent Atrial Fibrillation in HF: Medications vs AV Node Ablation/Pacing vs AF Ablation

Splanchnic Nerve Ablation for Treatment of HF Across the Spectrum of LV EFs

GSN Ablation Reduces Estimated Stressed Blood Volume in HFpEF: Supports REBALANCE-HF Mechanism of Action

Case Presentation

Position 2: All You Need Is Rate Control

Position 1: Ablate

Win Ratio Analysis of Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: REBALANCE-HF Randomized Trial

Greater Splanchnic Nerve Ablation for HFpEF

Is There a Difference in the Benefits of AF Ablation in HFrEF vs HFpEF?

The Role of AF Ablation in HF Across the Spectrum of Ejection Fractions

PVC-Induced Cardiomyopathy: Ablation Is the Treatment of Choice

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: REBALANCE-HF Randomized Trial 12-Month Results

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: Differences in Medication Changes in in the Sham and Treatment groups of REBALANCE-HF

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: REBALANCE-HF Stress Blood Volume Analysis

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: Updated Results of the REBALANCE-HF Trial Roll-in Cohort

Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF

Long-term follow-up on FIH experience using the Satera Ablation System in HFpEF and HFrEF

Overview of the physiology of the splanchnic bed in HFpEF and HFrEF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content